中国生物制药获批上市洛索洛芬钠凝胶贴膏
财中社2月7日电 中国生物制药（01177）发布公告，宣布其开发的“洛索洛芬钠凝胶贴膏”已获得中国国家药品监督管理局的上市批准。该产品主要用于缓解骨关节炎、肌肉痛及外伤引起的肿胀疼痛，是国内唯一一款通过一致性评价并经过临床试验验证上市的洛索洛芬钠凝胶贴膏。
洛索洛芬钠作为一种苯丙酸类非甾体消炎药，具有良好的安全耐受性，与其他非甾体抗炎药相比，其外用形式能够提高药物在疼痛部位的局部浓度，避免肝脏首过效应，提升疗效，同时减少胃肠道刺激。此次上市的产品将进一步增强公司的产品线，尤其是在镇痛外科领域，为患者提供更多的治疗选择，保障用药安全。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10